Previous 10 | Next 10 |
Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates Canada NewsWire Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and adva...
The following slide deck was published by Fusion Pharmaceuticals Inc. in conjunction with this event. For further details see: Fusion Pharmaceuticals (FUSN) Presents At Bloom Burton & Co. Healthcare Investor Conference - Slideshow
Gainers: Vivakor (VIVK) +91%. Digital World Acquisition (DWAC) +33%. Studio City International Holdings (MSC) +31%. Tempest Therapeutics (TPST) +30%. PAVmed (PAVM) +17%. AppTech Payments (APCX) +16%. Priority Technology Holdings (PRTH) +14%. Fusion Pharmaceuticals (FUSN) +14%. Alkermes ...
Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire HAMILTON, ON and BOSTON , April 26,...
Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...
Fusion Pharmaceuticals press release (NASDAQ:FUSN): Q4 GAAP EPS of -$0.40 beats by $0.09. Revenue of $0.6M. For further details see: Fusion Pharmaceuticals GAAP EPS of -$0.40 beats by $0.09, revenue of $0.6M
Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates Canada NewsWire - Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZeneca - Recently signed research collabora...
Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference Canada NewsWire HAMILTON, ON and BOSTON , Feb. 28, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing nex...
Fusion Pharmaceuticals (NASDAQ:FUSN) announced that the compensation committee of its board granted stock option awards to purchase 12.6K shares of its stock to one employee outside Fusion's 2020 Stock Option and Incentive Plan. The options have an exercise price of $8.07/share; eac...
Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference Canada NewsWire HAMILTON , ON and BOSTON, Jan. 21, 2022 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on devel...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...